Paul Capital invests in Indian drugmaker
The US-based firm will use its royalty fund to help the company develop a US portfolio of dermatology drugs.
16 January 2013•2 mins read
The US-based firm will use its royalty fund to help the company develop a US portfolio of dermatology drugs.
